


AstraZeneca 

IAP4 Rec'd PCT/PTO 20 DEC 2005 *PCT*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/550,039	Applicant: Gravestock <i>et al</i>
Filing Date: September 21, 2005	Attorney Docket No.: 100870-1P US
Examiner: Not yet known	Group Art Unit : Not yet known
Customer No.: 44992	Confirmation No.: Not yet known
Title: ANTIBACTERIAL 1,3-OXAZOLIDIN -2-ONE DERIVATIVES	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 12, 2005



Signature
Audrey Williams

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the **first Office Action** on the merits.

It is respectfully requested that each of the patents listed on the attached Form SB08A, and other information contained herein, be considered by the Examiner and made of record in this application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100870-1P US.

Respectfully submitted,



Name: Heidi M. Berven
Dated: December 12, 2005
Reg. No.: 48,951
Phone No.: 781-839-4336

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Form SB08A (1 page)
Documents
IPER
Search Report
Postcard Receipt

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/550,039
Filing Date	September 21, 2005
First Named Inventor	Michael Barry Gravestock
Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket No.	100870-1P US

SHEET of

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AA	WO 01/81350 A1	11-01-2001	AstraZeneca AB AstraZeneca UK Ltd		<input type="checkbox"/>
	AB	WO 02/081470 A1	10-17-2002	AstraZeneca AB AstraZeneca UK Ltd		<input type="checkbox"/>
	AC	EP 0352 781 A2/A3	01-31-1990	E.I. Du Pont De Nemours and Company		<input type="checkbox"/>
	AD	WO 99/64416 A2/A3	12-16-1999	Zeneca Ltd		<input type="checkbox"/>
	AE	WO 03/035648	05-01-2003	AstraZeneca AB AstraZeneca UK Ltd		<input type="checkbox"/>
	AF	WO 03/072576 A2/A3	09-04-2003	AstraZeneca AB AstraZeneca UK Ltd		
	AG	WO 03/072575	09-04-2003	AstraZeneca AB AstraZeneca UK Limited		<input type="checkbox"/>
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.